Future Directions in Publishing and Sharing RWE Case Studies with Regulators In recent years, Real-World Evidence (RWE) has gained significant traction as a valuable tool for informing regulatory decisions. The U.S. Food and Drug Administration (FDA) has indicated a willingness to accept RWE in its review of clinical data to support regulatory approvals. This article serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and data standards professionals in pharma and medtech. It explores the future directions of publishing and sharing FDA case studies approved products supported by RWE, analyzing regulatory expectations, precedents, and frameworks…

Scenario Planning for Best and Worst Case RWE Review Outcomes As the landscape of pharmaceuticals and medical devices continues to evolve, the significance of Real-World Evidence (RWE) in regulatory submission processes has grown dramatically. Professionals in the fields of regulatory affairs, biostatistics, Health Economics and Outcomes Research (HEOR), and data standards must systematically navigate the complex regulatory expectations established by the FDA, particularly in cases that involve RWE. This article serves as a step-by-step guide on scenario planning for best and worst-case outcomes in RWE reviews, including FDA case studies of approved products supported by RWE. Understanding Real-World Evidence (RWE)…

Incorporating Case Study Insights into Integrated Evidence Planning As regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), Real-World Evidence (RWE), and data standards professionals in pharma and medtech navigate the evolving landscape, the integration of case study insights becomes vital. This tutorial offers a comprehensive, step-by-step guide on how to utilize insights from FDA case studies of approved products supported by RWE. We will outline regulatory expectations and present relevant precedents that can serve as a model for developing integrated evidence plans. Understanding RWE and Its Role in Regulatory Submissions Real-World Evidence is derived from data collected outside of traditional…

Risk Sharing and Outcomes Based Contracts Informed by RWE Case Learnings In recent years, the integration of Real-World Evidence (RWE) into regulatory frameworks has transformed the manner in which pharmaceutical and medical device products are developed, evaluated, and approved. As regulatory bodies like the FDA articulate clearer expectations concerning RWE, the advent of risk-sharing agreements (RSAs) and outcomes-based contracts (OBCs) have emerged as critical strategies to mitigate risk and enhance the value proposition of therapies in the commercial landscape. This article provides a detailed step-by-step tutorial tailored for professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and…

Global comparison of FDA, EMA and HTA RWE case study portfolios Global Comparison of FDA, EMA and HTA RWE Case Study Portfolios Real-World Evidence (RWE) has emerged as a critical component in the regulatory approval process, particularly for the US Food and Drug Administration (FDA) and its counterparts in Europe, such as the European Medicines Agency (EMA) and Health Technology Assessment (HTA) agencies. This article aims to provide a comprehensive and detailed analysis regarding FDA case studies approved products supported by RWE, along with comparable insights from EMA and HTA perspectives. For professionals involved in regulatory compliance, biostatistics, health economics…